Anzeige
Meldung des Tages: NATO-Boom und Analysten-Kursziel +100 %: Steht hier der nächste Highflyer bereit?

Atara Biotherapeutics News

Aktie
WKN:  A40DQJ ISIN:  US0465132068 US-Symbol:  ATRA Branche:  Biotechnologie Land:  USA
5,64 $
+0,58 $
+11,46%
4,7799 € 20:47:37 Uhr
Depot/Watchlist
Marktkapitalisierung *
70,71 Mio. €
Streubesitz
19,86%
KGV
-
Index-Zuordnung
-

Atara Biotherapeutics News

12.02.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA PR Newswire
29.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA PR Newswire
22.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA PR Newswire
03.11.25 - PR Newswire
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-​Barr Virus ...
24.07.25 - PR Newswire
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-​Barr ...
15.07.25 - PR Newswire
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. PR Newswire
14.02.25 - PR Newswire
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws PR Newswire
11.02.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA PR Newswire
04.02.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA PR Newswire
28.01.25 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA PR Newswire
28.01.25 - PR Newswire
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm PR Newswire
21.01.25 - PR Newswire
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA PR Newswire
02.02.24 - PR Newswire
Atara Biotherapeutics und Pierre Fabre Laboratories geben Veröffentlichung von Phase-3-Daten zu ALLELE Tab-cel® in der Fachzeitschrift „The Lancet Oncology" bekannt
Atara Biotherapeutics und Pierre Fabre Laboratories geben Veröffentlichung von Phase-3-Daten zu ALLELE Tab-cel® in der Fachzeitschrift „The Lancet Oncology" bekannt PR Newswire
01.02.24 - PR Newswire
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology
Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology PR Newswire
20.09.23 - PR Newswire
Thinking about buying stock in VinFast Auto, Lilium, Exscientia, Atara Biotherapeutics, or Bird Global?
Thinking about buying stock in VinFast Auto, Lilium, Exscientia, Atara Biotherapeutics, or Bird Global? PR Newswire
08.02.23 - PR Newswire
Nach erteilter Marktzulassung für EBVALLO® (Tabelecleucel) durch die Europäische Kommission: Pierre Fabre vermarktet und vertreibt erste zugelassene allogene T-Zell-Immuntherapie in Europa
Nach erteilter Marktzulassung für EBVALLO® (Tabelecleucel) durch die Europäische Kommission: Pierre Fabre vermarktet und vertreibt erste zugelassene allogene T-Zell-...
19.12.22 - PR Newswire
Ebvallo® (Tabelecleucel) von Atara Biotherapeutics erhält die Zulassung der Europäischen Kommission als erste Therapie für Erwachsene und Kinder mit EBV+ PTLD
Ebvallo® (Tabelecleucel) von Atara Biotherapeutics erhält die Zulassung der Europäischen Kommission als erste Therapie für Erwachsene und Kinder mit EBV+ PTLD PR Newswire
19.12.22 - PR Newswire
Atara Biotherapeutics' Ebvallo® (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD
Atara Biotherapeutics' Ebvallo® (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD PR Newswire
15.10.22 - PR Newswire
CHMP empfiehlt die Zulassung von Ebvallo™ (Tabelecleucel) von Atara Biotherapeutics zur Behandlung der Epstein-Barr-Virus-positiven lymphoproliferativen Posttransplantationserkrankung
CHMP empfiehlt die Zulassung von Ebvallo™ (Tabelecleucel) von Atara Biotherapeutics zur Behandlung der Epstein-​Barr-Virus-positiven lymphoproliferativen ...
29.09.22 - PR Newswire
Thinking about buying stock in BigBear.ai, Bed Bath & Beyond, Atara Biotherapeutics, Stabilis Solutions, or Biomerica?
Thinking about buying stock in BigBear.ai, Bed Bath & Beyond, Atara Biotherapeutics, Stabilis Solutions, or Biomerica? PR Newswire

Newssuche

Videos

newspaper
25.02.26
So beeinflussen Margins DEIN Trading
Börsentäglich ab 18 Uhr Feierabend-​Trading Live. Teilnahme kostenlos mit diesem Link ... Mehr »